Evidence map›Paper›PMID 42618711›Full record

ArticleScientific reports2026

Vaccination-first immune priming shapes a sustained mRNA vaccine-induced IgG4 class switch that associates with SARS-CoV-2 breakthrough infection risk.

Tamás Pongrácz, Ulrika Marking, Oscar Bladh, Katherina Aguilera, Matilda Berkell, Sebastian Havervall, Nina Greilert-Norin, Jan Nouta, Steinar Gijze, Anna Wasynczuk and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tamás PongráczDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. tamas.pongracz@ki.se.ORCID 0000-0002-8089-4352
Ulrika MarkingDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Oscar BladhDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Katherina AguileraDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Matilda BerkellDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Sebastian HavervallDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Nina Greilert-NorinDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Jan NoutaCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Steinar GijzeCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Anna WasynczukCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Mikael ÅbergDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Gestur VidarssonImmunoglobulin Research Laboratory, Sanquin Research, Amsterdam, The Netherlands.
Youjia ZhongDepartment of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
David Falck *Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Charlotte Thålin *Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. charlotte.thalin@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Repeated administration of mRNA vaccines against SARS-CoV-2 has been associated with qualitative changes in antibody responses, including the emergence of non-inflammatory IgG4 subclasses and changes in Fc glycosylation. While neutralizing antibody titers remain key correlates of protection, potential functional implications of these structural antibody features warrant further investigation across age groups and multiple mRNA vaccine boosters. We characterized spike-specific IgG responses-including subclasses and Fc glycosylation patterns-using a liquid chromatography-mass spectrometry-based approach across six mRNA vaccine doses in a Swedish healthcare worker cohort (n = 104) and across three mRNA doses in a Singaporean pediatric cohort (n = 18). Repeated mRNA vaccination induced an IgG4 class switch which was sustained across at least six doses. This response associated with an increased risk of breakthrough infection (HR = 1.83, p = 0.028) in infection-naïve individuals (n = 41) lacking mucosal IgA responses that would potentially confound the interpretation of systemic IgG4‑related infection outcomes. Moreover, the IgG4 class switch was preceded with high early IgG1 Fc fucosylation signatures. Notably, these IgG structural changes were observed primarily in individuals who were naïve to SARS-CoV-2 at the time of first vaccination. Similar IgG structural features were observed across three mRNA doses in the small infection-naive pediatric cohort. Our results illustrate an IgG4-dominated immunological signature in both adults and children and highlight that immune priming by prior infection may shape subsequent mRNA vaccine-induced antibody responses. While these findings do not call into question the efficacy or safety of the widely adapted mRNA vaccine platform, they may have implications that merit further investigation.

Indexed as

COVID-19COVID-19 VaccinesImmunoglobulin Class SwitchingImmunoglobulin GSARS-CoV-2AdolescentAdultAntibodies, NeutralizingAntibodies, ViralBreakthrough InfectionsChildChild, PreschoolFemaleGlycosylationHumansMaleAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, CoronavirusVaccines, SyntheticBreakthrough infection riskClass switchIgG4IgG glycosylationmRNA vaccination

Identifiers

PMID42618711
PMCPMC13490519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.